Kornimate/medical-research-clean huggingface dataset:
ecchymosis and coldness in patients with varicose vein

Conditions: Varicose Veins; Chronic Venous Insufficiency; Symptoms and General Pathology

Summary: in this prospective, observational study, the investigators aim to investigate the symptoms of varicose vein patients.

chronic venous disease is very common in all over the world and affects both the mortality and morbidity depending on the effected vascular territory. it is often overlooked by healthcare professionals due to the underestimation of the prevalence and impact of the disease. it represents a spectrum of conditions varying from simple telangiectasia or reticular veins to skin fibrosis and venous ulceration. the main clinical characteristics are dilated veins, edema, leg pain, and cutaneous alterations in the legs. varicose veins are dilating superficial veins, which become more tortuous and enlarged, continuously. chronic venous disease affects the life quality of patients suffering from the disease, which can be measured with quality-of-life reports. venous insufficiency epidemiological and economic study-quality of life/symptoms (veines-qol/sym) questionnaire is a patient based, designed for self-completion instrument to measure both the symptom severity and quality of life. veines-qol measures life quality and veines-sym provides an overall estimate of cvd symptom frequency. from the practitioners daily knowledge of patients with varicose veins, there is a significant proportion of varicose vein patients also suffering from symptoms such as coldness and ecchymosis. in this context, the investigators aim to investigate the symptoms of participants with varicose vein using the veines-sym questionnaire.

Eligibility criteria:
inclusion criteria: * acceptance of inclusion * aged between 18-75 years exclusion criteria: * \< 18 year old * \> 75 year old * malignancy * active infection * hematological disease (severe anemia, leukemia, polistemia vera, sickle cell disease) * collagen tissue disease * severe decompensated heart failure (ejection fraction \< 40%) * cor pulmonale * rheumatoid arthritis * degenerative arthritis * history of lower extremity orthopedic surgery * lombar disk hernia * history of coronary artery by-pass surgery * severe psychiatric and neurological disease (parkinson disease, schizophrenia, bipolar disease, alzheimer disease, etc.) * peripheral arterial disease ( history of interventional procedure, claudication, active ischemic complaints)

Keywords: varicose veins chronic venous disease ecchymosis symptoms
modern urodynamics system efficacy (muse) study

Conditions: Urologic Diseases; Urodynamics

Summary: the goal of this prospective trial is to evaluate the feasibility, efficacy, and safety of the glean urodynamics system (gus) for use in the clinic to collect vesical pressure data in adult males and females with lower urinary tract symptoms. the main question\[s\] it aims to answer are: • what is the feasibility, efficacy, and safety of gus for use in clinical to collect vesical pressure data in adult males and females with lower urinary tract symptoms? participants will undergo a planned conventional urodynamics exam after which the glean sensor will be inserted and ambulatory urodynamics will be performed with the sensor indwelling in the bladder after which the sensor will be removed.


Eligibility criteria:
inclusion criteria: * male or female patient must be ≥ 18 years of age * patient must have a diagnosis of lutd * patient must be scheduled for or recommended for cuds * patient is able to tolerate 18fr catheterization * patient or patient's legally authorized representative is able to provide informed consent exclusion criteria: * pregnant (as confirmed by urine pregnancy test) or breastfeeding, pregnant within the past 6 months or intend to become pregnant during the study period. * patient has a symptomatic uti based on cdc guidance (see below) * subjects who, at the principal investigator's determination, would not be appropriate for this study.

Keywords: lower urinary tract dysfunction urinary incontinence overactive bladder urodynamics uroflowmetry
laparoscopy-assisted transanal endoscopy rectosigmoid resection for rectal cancer

Conditions: Adenocarcinoma of the Rectum

Summary: transanal endoscopic rectosigmoid resection with laparoscopic assistance was developed at massachusetts general hospital and performed successfully to remove cancer of the lower rectum. based on the outcomes, the research doctors believe that this investigational surgery may be as safe and effective as standard laparoscopic or open surgery performed to remove rectal cancer, may facilitate the operation and reduce the size of the abdominal incisions. in this research study, the investigators are looking to see if this investigational procedure is a safe and effective approach to remove rectal cancer of the mid and lower rectum.

subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. at the end of the procedure, the rectum will be removed though the anus, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.

Eligibility criteria:
inclusion criteria: * biopsy-proven adenocarcinoma of the rectum * eligible to undergo standard open or laparoscopic low anterior resection with a temporary diverting stoma * node negative (n0), t1 (high risk features), t2 and t3 rectal cancer on pelvic mri * closest distance between tumor edge and mesorectal fascia 5mm or more based on pelvic mri * rectal cancer located 4-12 cm from the anal verge * ecog performance status 2 or less exclusion criteria: * metastasis * obstructing rectal cancer * synchronous colon cancer * t3 rectal cancer not treated preoperatively with full-course chemoradiation * pregnant or breast-feeding * receiving any other study agents * fecal incontinence * history of prior colorectal cancer * history of inflammatory bowel disease * history of pelvic radiation * prior pelvic surgery or multiple abdominal procedures * bmi \> 30 * large uterine fibroids * uncontrolled intercurrent illness * other malignancies diagnosed within the previous year, except basal cell cancer

Keywords: rectal cancer
radiant warmer trial

Conditions: Body Temperature Changes

Summary: the purpose of this study is to compare three radiant warmer beds that contain different computer heating software and different bed styles. radiant warmers are used in many neonatal intensive care units (nicu) to provide heat to infants to help regulate an infant's temperature. it is common for babies to require care on an open bed that provides heat to the baby according to the baby's needs and at the same time allows easy access to the baby for care and necessary procedures. there are different styles of beds, each with unique computer software that can guide how a bed's heater output is automatically adjusted according to a baby's temperature needs. it is unknown which style of bed or method of heating might be best. this study seeks to evaluate infant responses to three different types of radiant warmer beds.

study was withdrawn

Eligibility criteria:
inclusion criteria: * any baby \> 32 weeks gestation and \> 1500 grams that requires initial care on a radiant warmer during confinement in the neonatal intensive care unit. exclusion criteria: * any baby who has a skin condition that may prevent or compromise thermistor placement and interfere with accurate temperature readings from thermistors or ir camera. * any baby who is deemed too sick to tolerate movement from one radiant warmer to another by the attending physician. * any baby who has a medical condition or anomaly that contraindicates axillary or abdominal temperature measurements
effort extension study

Conditions: Hepatitis B, Chronic

Summary: * the purpose of this study is to to prove that the long-term efficacy of strategy of treatment adjustment at w24 according to virological response based on roadmap concept is better than standard of care strategy. * to evaluate the off-treatment durability of hbeag seroconversion in patients who discontinued treatment due to sustained hbeag seroconversion and hbv dna\<300copies/ml with over 12 months consolidation treatment


Eligibility criteria:
inclusion criteria: * treated with telbivudine or combined with adefovir in effort study * patients are willing to participate in the extension study * patients provide information consent form exclusion criteria: * adjustment of poor compliance by investigators

Keywords: chronic hepatitis b compensated chronic hepatitis b
re-examination study of emend (aprepitant) (mk-0869-184)

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: this survey is conducted for preparing application materials for re-examination under the pharmaceutical affairs laws and its enforcement regulation. its aim is to reconfirm the clinical usefulness of ememd (aprepitant) through collecting the safety information according to the re-examination regulation for new drugs.


Eligibility criteria:
inclusion criteria: * participants who are treated with emend for the first time as per the emend label exclusion criteria: * contraindication to emend

Keywords: nausea vomiting chemotherapy post-chemotherapy
comparison between efficiency of inferior alveolar nerve block and buccal infiltration techniques using articaine 4% 1:100000

Conditions: Anesthesia, Local

Summary: this split mouth randomized control trial is designed as to compare the effectiveness of the buccal infiltration technique with the gold standard inferior alveolar nerve block in anesthetizing mandibular second primary molars to undergoing pulpal treatment. patient will be videotaped during pulpal treatment of their teeth and an accessing pain will be through an objective pain scale (sem scale), (sound-eye-motor scale). the patient will be asked to fill in a subjective wong baker pain scale for the pain suffered during injecting the local anesthetic agent in both techniques.


Eligibility criteria:
a-inclusion criteria: 1. first dental visit. 2. cooperative children (rating 4 or 3 based on frankl behavior scale) aging from 6 to 8 years suffering from one or more deep carious lesions in their primary molars seeking treatment. 3. restorable molars with stainless steel crowns. b-exclusion criteria: 1. medically compromised patients. uncooperative children (rating 1 or 2 on the frankl behavior scale)needing special line of treatment through general anesthesia. 2. signs and symptoms of irreversible pulpitis, spontaneous pain, necrosis or any signs or symptoms of any infection. 3. presence of any radiographic signs of abcess, bone loss, internal or external root resorption. 4. parents or guardians who refuse participating in the study.

Keywords: pediatric patients articaine local anesthesia
green tea, high in epigallocatechin gallate (egcg) and postprandial fat oxidation

Conditions: Obesity; Type 2 Diabetes Mellitus

Summary: the body of evidence regarding the health benefits of green tea has grown considerably during the last decade and includes antioxidant properties, anti- cancer, anti-obesity and anti-diabetes effects. there has been evidence that green tea extract favorably affect body weight and body fat and has positive effects on blood glucose control aim of this study is to investigate the short term effect (3-day)of teavigo (high in the catechin egcg) on postprandial fat oxidation during different phases of the postprandial period in overweight subjects. secondly, in a subset of volunteers changes in lipolysis and glucose metabolism will be studied in skeletal muscle and adipose tissue.


Eligibility criteria:
inclusion criteria: * age between 20 and 50 y * bmi 25.0-29.9 kg/m2 * normal fasting glucose \<6.1 mmol/l * blood pressure (systolic blood pressure 100-150 mmhg, diastolic blood pressure 60-90 mmhg) * weight stable in last 3 months (±2 kg) exclusion criteria: * pregnant, lactating or (post)menopausal women * regular smokers * people with intensive fitness training eg athletes * habitual consumption of green or black tea (more than 1 or 2 cups a day, respectively) * not more than 300 mg/day caffeine consumption
clomiphene citrate in combination with gonadotropins for ovarian stimulation in women with poor ovarian response.

Conditions: Female Infertility

Summary: coadministration of various drugs used for ovarian stimulation can increase the efficiency of ivf especially in poor responders. the investigators hypothesize that ovarian response of those patients could improve by using combination of clomiphene citrate with gonadotropins in infertile women with poor response to gonadotrophin administration only.

patients diagnosed with poor ovarian response will be included in the study. the definition of poor response was based on the presence of at least one of the following criteria: age \> 40 years old, day 2 fsh \>9.5 miu/ml, amh \< 2ng/ml ,at least one previous coh with less than 3 oocytes retrieved, at least one cancelled attempt due to poor response, estradiol less than 500 pg/ml on the day of hcg. all patients will be counseled regarding their prognosis and other treatment options including oocyte donation as well as adoption were also presented and discussed in detail. early follicular phase fsh, estradiol (e2) and anti-mullerian hormone (amh) will be measured prior to the initiation of treatment. women in the clomiphene group will receive 100-150 mg of clomiphene citrate once per day for 5 days in combination with gonadotropins according to short gnrh-antagonist protocol: all women will have measurements of serum fsh and estradiol and a pelvic sonogram on the second day of their cycle. providing that serum fsh is \< 17 miu/ml and estradiol is \< 70 pg/ml on day 2 , ovarian stimulation will be initiated with 100-150 mg of clomiphene citrate in combination with 450 iu of gonadotropins either in the form of a combination of highly purified urinary fsh and lh or with a combination of rec fsh and rec lh. all patients will be re-evaluated on day 5 of the stimulation, and dosage adjustments will be made and the antagonists (cetrorelix or ganirelix 0.25 mg/day) will be initiated. when at least 2 follicles reach an average diameter of 17 mm, final oocyte maturation will be triggered with 10,000iu of hcg ( pregnyl, organon, greece inc.). oocyte retrieval will be performed 34 to 36 hours later. all patients will undergo icsi. patients with successful fertilization will have embryo transfer under sonographic guidance on day 3 after retrieval. women in the gonadotropin group will receive only gonadotropins according to short gnrh-antagonist protocol as it was mentioned above.

Eligibility criteria:
inclusion criteria: * women with poor response to ovarian stimulation. the definition of poor response was based on the presence of at least one of the following criteria: age \> 40 years old, day 2 fsh \>9.5 miu/ml, amh \< 2ng/ml ,at least one previous coh with less than 3 oocytes retrieved, at least one cancelled attempt due to poor response, estradiol less than 500 pg/ml on the day of hcg. exclusion criteria: * all other women that do not fulfill the above mentioned criteria

Keywords: clomiphene citrate ivf pregnancy rates ovarian reserve
all-trans retinoic acid in combination with standard induction and consolidation therapy in older patients with newly diagnosed acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: this is a study looking at all-trans retinoic acid in combination with standard induction and consolidation therapy in older patients with newly diagnosed acute myeloid leukemia (aml).

first induction therapy: * cytarabine 100 mg/m² cont. i.v. days 1-5 * idarubicin 12 mg/m² i.v. days 1, 3 * atra 45 mg/m² p.o. days 4-6, atra 15 mg/m² p.o. days 7-28 second induction therapy: * cytarabine 100 mg/m² cont. i.v. days 1-5 * idarubicin 12 mg/m² i.v. days 1, 3 * atra 45 mg/m² p.o. days 4-6, atra 15 mg/m² p.o. days 7-28 first consolidation therapy: * cytarabine 1000 mg/m² bid i.v. days 1-3 * mitoxantrone 10 mg/m² i.v. days 2, 3 * atra 15 mg/m² p.o. days 4-28 second consolidation therapy * etoposide 100 mg/m² i.v. days 1-5 * idarubicin 12 mg/m² i.v. days 1,3 * atra 15 mg/m² p.o. days 4-28

Eligibility criteria:
inclusion criteria: * newly diagnosed aml defined according to the world health organization (who) classification (excluding acute promyelocytic leukemia \[apl\]) * aged \> 60 years * all patients have to be informed about the character of the study. written informed consent of each patient at study entry. * molecular and cytogenetical analyses on initial bone marrow and peripheral blood specimen have to be performed at the central reference laboratories. exclusion criteria: * bleeding independent of the aml * acute promyelocytic leukemia * uncontrolled infection * participation in a concurrent clinical study * insufficiency of the kidneys (creatinine \> 1.5 x upper normal serum level), of the liver (bilirubin, ast or ap \> 2 x upper normal serum level), severe obstruction or restrictive ventilation disorder, heart failure new york heart association \[nyha\] iii/iv * severe neurological or psychiatric disorder interfering with ability of giving informed consent * no consent for the registration, storage and processing of data concerning the characteristics of the aml and the individual course * performance status who \> 2

Keywords: age > 60 years
clinical efficacy and safety evaluation of co-administered hgp0904, hgp0608 and hgp0816 in patients with hypertension and dyslipidemia

Conditions: Hypertension; Hyperlipidemia

Summary: a phase 3 study to evaluate efficacy and safety of co-administered hgp0904, hgp0608 and hgp0816 in patients with hypertension and dyslipidemia

this study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial to evaluate the efficacy and safety of co-administered hgp0904, hgp0608 and hgp0816 in patients with hypertension and dyslipidemia

Eligibility criteria:
inclusion criteria: 1. 19 ≤ age ≤ 75 2. at visit 1 1) bp: sitdbp ≥ 90mmhg 2) cholesterol : ldl-c ≤ 250mg/dl, tg \< 400mg/dl 3. at visit 2 : after tlc (after 4weeks) 1) bp: 80 mmhg ≤ sitdbp \ 20 ,100mg/dl ≤ ldl-c ≤ 250mg/dl 3) tg \< 400mg/dl 4. patients understood the contents and purpose of this trial and signed informed consent form exclusion criteria: 1. at visit 1, bp difference sbp ≥20mmhg or dbp ≥10mmhg 2. tolerance or hypersensitivity angiotensin ii receptor blocker or hmg-coa. reductase inhibitor, calcium channel blocker(dihydropyridine) or multi-drug allergy 3. fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin 4. cpk normal range ≥ 3times 5. uncontrolled primary hypothyroidism(tsh normal range ≥ 2 times) 6. renal disease or suspected renal disease (scr ≥ 2mg/dl, ast or alt≥2 times) 7. active gout or hyperuricemia(at visit 1, uric acid \> 9mg/dl) 8. iddm or uncontrolled diabetes mellitus (hba1c\>9%) 9. ventricular arrhythmia 10. medical history * severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertension * encephalopathy, transient cerebral ischemic attack(tia) * severe heart disease(heart failure of nyha class iii-iv), valvular disease of heart or myocardial infarction and unstable angina * angioplasty or coronary artery bypass graft(cabg) surgery within 6months

Keywords: hypertension hyperlipidemia
amnion membrane versus dfgg using the tunneling technique in management of gingival recession defects.

Conditions: Gingival Recession

Summary: treatment of gingival recession is indicated mainly for esthetic reasons and keratinized tissue augmentation (zucchelli and mounssif, 2015). an array of surgical techniques has been proposed by the literature to cover gingival recession defects with well-documented successful outcomes. the selection of one technique over the other depends on many factors. some of these factors are related to the gingival recession defect itself, others are related to the anatomy of the palatal fibromucosa, or related to the patient variabilities (zucchelli and de sanctis, 2000). controversy exists in the literature regarding the patient morbidity after connective tissue graft harvesting. inconclusive postulations have been made about the post-operative patient morbidity outcomes and root coverage outcomes when comparing connective tissue graft harvesting in comparison to allograft membranes used for root coverage. the use of connective tissue graft in combination with root coverage techniques remain the gold standard for root coverage procedures. the problem with the connective tissue graft is that harvesting a graft from the palate increases morbidity, needs an extra surgical site which is more traumatic for the patient, depends on the donor tissue which could be limited, increases surgical chair-time and needs increased surgical skills (cortellini \& pini prato 2012). the rationale behind the use of amnion membrane is to avoid the morbidity inherent with connective tissue graft harvesting.


Eligibility criteria:
inclusion criteria: * age between 18 and 60 years. * periodontally and systemically healthy. * presence of rt1 or rt2 buccal gingival recession defects ≥2 mm in depth. * full-mouth plaque and bleeding score of \ 3 mm. * absence of non-carious cervical lesions (nccls) and non-detectable cemento-enamel junction (cej) at the defect sites. exclusion criteria: * rt3 recession defects. * smokers as smoking is a contraindication for any plastic periodontal surgery (khuller, 2009). * presence of caries lesions or restorations in the cervical area. * intake of medications which impede periodontal tissue health and healing. * medical contraindications for periodontal surgical procedures. * uncooperative patients not willing to complete the follow up period. * pregnancy and lactation.
retinal layers and visual rehabilitation after epiretinal membrane removal

Conditions: Epiretinal Membrane

Summary: the purpose of this study is to evaluate the changes in visual acuity, metamorphopsia, and thickness of retinal layers after epiretinal membrane removal and to investigate factors associated with visual function.

eyes with idiopathic epiretinal membrane removal (erm) scheduled to underwent erm removal were included. changes in visual acuity, metamorphopsia score (m-score) using m-chart, and parafoveal thickness of each retinal layer were evaluated preoperatively and at 2-month and 6-month postoperative follow-up visits. factors associated with visual acuity and m-score were investigated.

Eligibility criteria:
inclusion criteria: * patients who were diagnosed with idiopathic epiretinal membrane and were scheduled for epiretinal membrane removal exclusion criteria: * evidence of ocular inflammation, diabetic retinopathy, hypertensive retinopathy, and retinal vasculitis, media opacity that would influence visual acuity or preclude acquisition of clear spectral domain optical coherence tomography images, * presence of cataract judged to affect visual function, -6.0 diopters or more of spherical equivalent, prominent staphyloma, history of intraocular surgery other than uncomplicated cataract surgery, history of retinal detachment, other ocular diseases that may influence the macular microstructure or visual function, immeasurable fovea location on the spectral domain optical coherence tomography image due to severe retinal contraction, and indistinct intraretinal structure on spectral domain optical coherence tomography images. * patients who underwent combined epiretinal membrane removal and cataract extraction, less than six months follow-up after epiretinal membrane removal, who had occurrence or progression of cataract after the surgery judged to affect visual function, or who experienced recurrence of epiretinal membrane during the follow-up period

Keywords: epiretinal membrane visual acuity metamorphopsia thickness of retinal layers spectral domain optical coherence tomography